everolimus NDC 59651-933

NDC codes

FDA NDC Directory

Product NDC (as listed)59651-933Labeler and product segments. Claims need a package NDC.

Product NDC at billing width59651-0933Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
59651-933-60	59651093360	60 TABLET in 1 BOTTLE (59651-933-60)Marketed from Feb 25, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): everolimus
Generic name (nonproprietary): everolimus
Active ingredients: Everolimus — .75 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aurobindo Pharma Limited
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219533
Marketing start: Feb 25, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2D6 Inhibitors (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Immunologic Activity (Physiologic effect)Protein Kinase Inhibitors (Mechanism)mTOR Inhibitors (Mechanism)
Identifiers: Product ID 59651-933_43ef3c29-0e25-4fdd-aea1-06a20af9bbabSPL ID 43ef3c29-0e25-4fdd-aea1-06a20af9bbabSPL set ID 43ef3c29-0e25-4fdd-aea1-06a20af9bbabRxCUI 977427, 977434, 977438, 2056895UNII 9HW64Q8G6GUPC 0359651933602, 0359651934609, 0359651931608, 0359651932605
Pharmacologic class: Kinase Inhibitor; mTOR Inhibitor Immunosuppressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N459651093360 followed by a unit qualifier and the quantity

Package 59651-0933-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 26, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: Kidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids ( 1.1 ) Liver Transplant : Administer no earlier than 30 days posttransplant. Use in combination with tacrolimus (reduced doses) and corticosteroids ( 1.2 , 5.5 ) Limitations of Use : Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 ) 1.1 Prophyl…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 219533

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219533
Product	Strength	Form · route	Labeler	Product NDC
everolimus	Everolimus 1 mg/1	TabletOral	Aurobindo Pharma Limited	59651-934
everolimus	Everolimus .25 mg/1	TabletOral	Aurobindo Pharma Limited	59651-931
everolimus	Everolimus .5 mg/1	TabletOral	Aurobindo Pharma Limited	59651-932